BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 26473283)

  • 1. Second-generation prophylactic HPV vaccines: current options and future strategies for vaccines development.
    Fruscalzo A; Londero AP; Bertozzi S; Lellè RJ
    Minerva Med; 2016 Feb; 107(1):26-38. PubMed ID: 26473283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of clinical trials of human papillomavirus prophylactic vaccines.
    Schiller JT; Castellsagué X; Garland SM
    Vaccine; 2012 Nov; 30 Suppl 5(0 5):F123-38. PubMed ID: 23199956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of cervical cancer: journey to develop the first human papillomavirus virus-like particle vaccine and the next generation vaccine.
    Bryan JT; Buckland B; Hammond J; Jansen KU
    Curr Opin Chem Biol; 2016 Jun; 32():34-47. PubMed ID: 26994695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of human papillomavirus vaccination.
    Brotherton JM; Ogilvie GS
    Curr Opin Oncol; 2015 Sep; 27(5):399-404. PubMed ID: 26258273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results.
    Schiller JT; Castellsagué X; Villa LL; Hildesheim A
    Vaccine; 2008 Aug; 26 Suppl 10(Suppl 10):K53-61. PubMed ID: 18847557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic immunization with human papillomavirus vaccines induces oral immunity in mice.
    Ahn J; Peng S; Hung CF; Roden RBS; Best SR
    Laryngoscope; 2018 Jan; 128(1):E16-E20. PubMed ID: 28868617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.
    Capri S; Gasparini R; Panatto D; Demarteau N
    Gynecol Oncol; 2011 Jun; 121(3):514-21. PubMed ID: 21334734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced dose human papillomavirus vaccination: an update of the current state-of-the-art.
    Toh ZQ; Licciardi PV; Fong J; Garland SM; Tabrizi SN; Russell FM; Mulholland EK
    Vaccine; 2015 Sep; 33(39):5042-50. PubMed ID: 26271829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
    Schwarz TF
    Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPV-vaccination against cervical carcinoma: will it really work?
    Gross G
    Med Microbiol Immunol; 2007 Sep; 196(3):121-5. PubMed ID: 17318575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GARDASIL: prophylactic human papillomavirus vaccine development--from bench top to bed-side.
    Shi L; Sings HL; Bryan JT; Wang B; Wang Y; Mach H; Kosinski M; Washabaugh MW; Sitrin R; Barr E
    Clin Pharmacol Ther; 2007 Feb; 81(2):259-64. PubMed ID: 17259949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HPV & HPV vaccination: issues in developing countries.
    Bharadwaj M; Hussain S; Nasare V; Das BC
    Indian J Med Res; 2009 Sep; 130(3):327-33. PubMed ID: 19901442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis.
    Malagón T; Drolet M; Boily MC; Franco EL; Jit M; Brisson J; Brisson M
    Lancet Infect Dis; 2012 Oct; 12(10):781-9. PubMed ID: 22920953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Nine-valent HPV vaccine - new generation of HPV vaccine].
    Fait T; Dvořák V; Pilka R
    Ceska Gynekol; 2015 Dec; 80(6):397-400. PubMed ID: 26741152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18.
    Goldstone SE; Vuocolo S
    Expert Rev Vaccines; 2012 Apr; 11(4):395-406. PubMed ID: 22551023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
    Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
    Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine.
    Luxembourg A; Bautista O; Moeller E; Ritter M; Chen J
    Contemp Clin Trials; 2015 May; 42():18-25. PubMed ID: 25749310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human papillomavirus vaccines and vaccine implementation.
    de Sanjosé S; Alemany L; Castellsagué X; Bosch FX
    Womens Health (Lond); 2008 Nov; 4(6):595-604. PubMed ID: 19072462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of Human Papillomavirus Infection. Beyond Cervical Cancer: A Brief Review.
    Medeiros R; Vaz S; Rebelo T; Figueiredo-Dias M
    Acta Med Port; 2020 Mar; 33(3):198-201. PubMed ID: 32130098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [AN HPV-ASSOCIATED DISEASES AND CERVICAL CANCER AND PROPHYLACTIC HUMAN PAPILLOMAVIRUS (HPV) VACCINES].
    Malinova M
    Akush Ginekol (Sofiia); 2015; 54 Suppl 1():25-31. PubMed ID: 26137767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.